Midlife Brain Fog? It Could Be Early Alzheimer's, Especially for Women

• Alzheimer's can begin decades before symptoms appear, with brain changes starting as early as age 45.
• The disease systematically destroys nerve cell connections, affecting memory, language, and daily life functions.
• New drugs Lecanemab and Donanemab show promise in slowing cognitive decline in early stages, with Lecanemab slowing decline by 27% and Donanemab by 35%.
• Women are disproportionately affected by Alzheimer's, accounting for nearly two-thirds of all patients globally, with a 1 in 5 lifetime risk for a 45-year-old woman.
• Midlife, particularly perimenopause and the drop in estrogen, is a critical period for Alzheimer's prevention, emphasizing the importance of lifestyle and early medical attention for cognitive changes.

Key Questions Answered

How can midlife women proactively assess and mitigate their risk of developing Alzheimer's disease?

Midlife women can proactively assess and mitigate Alzheimer's risk by managing health conditions, adopting a brain-healthy diet, and considering genetic insights.

What are the long-term implications of new Alzheimer's drugs like Lecanemab and Donanemab for patient care?

New Alzheimer's drugs like Lecanemab and Donanemab show promise in slowing cognitive decline. Lecanemab slowed decline by 27% in mild impairment or early Alzheimer's.

Beyond medication, what lifestyle interventions show the most promise in preventing cognitive decline in women?

Lifestyle interventions showing promise in preventing cognitive decline in women include cardiovascular health, sleep, stress management, physical activity, and cognitive engagement.